Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis

INTRODUCTION: Phase I/II clinical trials suggested that the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway-targeted agents were active in suppression of gastric cancer (GC). Randomised controlled trials (RCTs) were undertaken assessing whether the addition of anti-HGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhiyuan, Cai, Zhaolun, Ma, Qin, Shen, Chaoyong, Yin, Yuan, Yin, Xiaonan, Liu, Chunyu, Chang, Chen, Zhao, Zhou, Mu, Mingchun, Zhang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712986/
https://www.ncbi.nlm.nih.gov/pubmed/34952869
http://dx.doi.org/10.1136/bmjopen-2021-049575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712986/
https://www.ncbi.nlm.nih.gov/pubmed/34952869
http://dx.doi.org/10.1136/bmjopen-2021-049575

Ejemplares similares